Ligelizumab treatment for severe asthma: learnings from the clinical development programme

OBJECTIVE: Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. This multi‐centre, randomised, double‐blind study was designe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Transl Immunology
Hlavní autoři: Trischler, Jordis, Bottoli, Ivan, Janocha, Reinhold, Heusser, Christoph, Jaumont, Xavier, Lowe, Phil, Gautier, Aurelie, Pethe, Abhijit, Woessner, Ralph, Zerwes, Hans‐Günter, Zielen, Stefan
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958305/
https://ncbi.nlm.nih.gov/pubmed/33747510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cti2.1255
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky